Loading
Diabetes Treatment and Management · Journal article
Diabetes Obesity and Metabolism · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This first-in-human Phase 1a/1b trial reports that the novel triple GLP-1/GIP/GCG receptor agonist UBT251 was generally well tolerated with predictable pharmacokinetics and encouraging pharmacodynamic signals including weight loss of 8.96–13.48 kg over 12 weeks in the overweight/obese cohort and improvements in metabolic markers. However, as an early-phase safety and tolerability study in a small population, these findings are preliminary and require confirmation in larger, longer, adequately powered Phase 2/3 trials before clinical recommendations can be made.
Randomized, double-blind, placebo-controlled Phase 1a/1b trial (single-ascending-dose and multiple-ascending-dose). Phase 1a: healthy participants (implied); Phase 1b: participants with overweight or obesity without diabetes. Intervention: UBT251 (triple GLP-1/GIP/GCG receptor agonist) subcutaneous injection at ascending doses. Compared with: Placebo.
In participants with overweight or obesity receiving once-weekly UBT251 for 12 weeks, mean body weight reduction was 8.96–13.48 kg at doses of 1, 3, and 6 mg, versus a 1.57 kg increase in placebo UBT251 exhibited approximately linear pharmacokinetics across the 1.0–6.0 mg dose range following single and multiple dosing UBT251 demonstrated reductions in fasting plasma glucose, haemoglobin A1c, and lipid parameters
Metabolic and weight-loss outcomes were pharmacodynamic observations, not primary endpoints Follow-up duration limited to 12 weeks; long-term safety and durability unknown
Clinicians should view these Phase 1 findings as proof-of-concept supporting continued development, but should not yet consider UBT251 for clinical use. Larger, longer Phase 2/3 trials comparing hard endpoints (cardiovascular, mortality, glycaemic control) against established therapies are needed.
First-in-human Phase 1a/1b trial with primary endpoints of safety and tolerability; pharmacodynamic weight loss and metabolic findings are encouraging but uncontrolled comparisons in a small, early-phase study cannot yet support practice changes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should view these Phase 1 findings as proof-of-concept supporting continued development, but should not yet consider UBT251 for clinical use. Larger, longer Phase 2/3 trials comparing hard endpoints (cardiovascular, mortality, glycaemic control) against established therapies are needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
AIMS: UBT251 is a novel triple agonist peptide targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This first-in-human Phase 1a/1b study evaluated the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of UBT251. MATERIALS AND METHODS: This randomized, double-blind, placebo-controlled study consisted of two clinical trials. The Phase 1a study was a single-ascending-dose trial, in which participants received a single subcutaneous injection of UBT251 at doses ranging from 0.1 to 4.5 mg. The Phase 1b study was a multiple-ascending-dose trial conducted in participants with overweight or obesity without diabetes. UBT251 was administered once weekly by subcutaneous injection for 12 consecutive weeks. Safety and tolerability were the primary endpoints. RESULTS: UBT251 was generally well tolerated, with laboratory investigations, decreased appetite and gastrointestinal adverse events being the most common adverse effects. In participants with overweight or obesity, once-weekly subcutaneous injections of UBT251 at doses of 1, 3 and 6 mg for 12 weeks led to a mean body weight reduction of 8.96-13.48 kg, compared with the 1.57 kg increase observed in the placebo group. Following single and multiple dosing, UBT251 exhibited approximately linear pharmacokinetics across the 1.0-6.0 mg dose range. UBT251 treatment also demonstrated favourable metabolic effects, including reductions in fasting plasma glucose, haemoglobin A1c and lipid parameters. CONCLUSIONS: UBT251 demonstrated an acceptable safety profile and predictable pharmacokinetic properties, accompanied by substantial weight reduction and meaningful metabolic improvements. These findings strongly support the continued clinical development of UBT251 as a potential therapeutic option for obesity and type 2 diabetes. TRIAL REGISTRATION: ChiCTR2600116148 and ChiCTR2600123803 (https://www.chictr.org.cn/).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.